Cultural perceptions, education, or financial status were found to shape attitudes surrounding acupuncture use as an integrative oncology therapy for patients who survived breast cancer, according to a poster presentation from the 2025 Oncology Nursing Society Congress.
A multivariate regression model found social determinants of health like financial resource needs (0.318; 95% CI, 0.10-0.53; P = .004), those who were White (0.563; 95% CI, 0.15-0.98; P = .009), had some college education or above (1.07; 95% CI, 0.51-1.62; P <.001), had some graduate school or above (0.96; 95% CI, 0.35-1.57; P = .002), or having arm pain (0.47; 95% CI, 0.07-0.88; P = .023) were found to be predictors of acupuncture treatment expectancy. Physical function was also assessed but was not a predictor of expectancy (–0.22; 95% CI, –0.44 to 0.01; P = .057).
Additionally, patients on the trial expected acupuncture to reduce cancer-related symptoms like pain and fatigue (4.2 ± 0.8), allow them to cope with their cancer (3.9 ± 1.0), decrease emotional distress (3.9 ± 1.0), and prevent future health problems (3.3 ± 1.1).
“Sociocultural influences may shape perception and attitudes toward complementary and integrative health therapies, and cultural perceptions of acupuncture vary across racial and ethnic groups,” Hannah Choi, MSN, RN, a graduate research assistant at the University of Illinois Chicago, wrote in the presentation.
The aim of the study was to identify factors that may influence acupuncture expectancy for survivors of breast cancer. Expectancy was defined as the belief a treatment will be effective. The authors highlighted that this is an important driver for treatment adherence and effectiveness.
Overall, 74 women who were 18 years or older with stage 0 to III breast cancer were enrolled. This study served as the secondary analysis of baseline data from 2 acupuncture trials with a 5 and 10-week intervention.
The primary end point was acupuncture expectancy which is described as a 4-item subscale of the Attitudes and Beliefs about Complementary and Alternative Medicine Questionnaire. Social determinants of health were described as an 8-domain, 11-item questionnaire looking at social detriments of health needs like financial resources, transportation, and social connection.
Age (54 ± 10 years), race (49% Black, 45% White, and 6% Asian or Pacific Islander), education level (18% high school or below), marital status (35% married or living with a partner), and annual household income (57% less than $55,000) all played a part in the baseline demographic and clinical characteristics.
The univariate regression analysis found significant findings in financial resources (0.34; 95% CI, 0.56-0.11; P = .004), patients who were White (0.46; 95% CI, 0.01-0.92; P = .046), education of college or above (0.71; 95% CI, 0.09-1.32; P = .026), some graduate school or above (0.76; 95% CI, 0.06-1.45; P = .033), having arm pain (0.46; 95% CI, 0.003-0.91; P = .049), depression (0.30; 95% CI, –0.07 to 0.30; P = .002), stress (0.24; 95% CI, 0.01-0.47; P = .038), or social connections (0.23; 95% CI, 0.001-0.46; P = .049).
Physical function (–0.18; 95% CI, –0.41-0.05; P = .121), fatigue (–0.03; 95% CI, –0.11 to .09; P = .077), anxiety (–0.30; 95% CI, –0.28 to 0.04; P = .052), cancer stage (0.21; 95% CI, –0.02 to 0.44; P = .073), and radiation therapy (–0.48; 95% CI, –1.05 to 0.09; P = .100) were also assessed but were not found to be significant.
“Understanding these individual factors affecting acupuncture expectancy can guide integration of acupuncture into oncology care to improve quality of life for breast cancer populations,” Choi concluded.
Reference
Choi H, Doorenbos AZ, Chen Z, et al. Factors associated with acupuncture expectancy among breast cancer survivors. Presented at the 2025 Oncology Nursing Society Congress; April 9-13; Denver, CO. Poster RS69.
Social Determinants of Health Affect Acupuncture Expectancy in Breast Cancer
Race, education, and arm pain were found to influence acupuncture expectancy in patients who are survivors of breast cancer.
Patients on the trial expected acupuncture to reduce cancer-related symptoms like pain and fatigue (4.2 ± 0.8), allow them to cope with their cancer (3.9 ± 1.0), decrease emotional distress (3.9 ± 1.0), and prevent future health problems (3.3 ± 1.1).
Cultural perceptions, education, or financial status were found to shape attitudes surrounding acupuncture use as an integrative oncology therapy for patients who survived breast cancer, according to a poster presentation from the 2025 Oncology Nursing Society Congress.
A multivariate regression model found social determinants of health like financial resource needs (0.318; 95% CI, 0.10-0.53; P = .004), those who were White (0.563; 95% CI, 0.15-0.98; P = .009), had some college education or above (1.07; 95% CI, 0.51-1.62; P <.001), had some graduate school or above (0.96; 95% CI, 0.35-1.57; P = .002), or having arm pain (0.47; 95% CI, 0.07-0.88; P = .023) were found to be predictors of acupuncture treatment expectancy. Physical function was also assessed but was not a predictor of expectancy (–0.22; 95% CI, –0.44 to 0.01; P = .057).
Additionally, patients on the trial expected acupuncture to reduce cancer-related symptoms like pain and fatigue (4.2 ± 0.8), allow them to cope with their cancer (3.9 ± 1.0), decrease emotional distress (3.9 ± 1.0), and prevent future health problems (3.3 ± 1.1).
“Sociocultural influences may shape perception and attitudes toward complementary and integrative health therapies, and cultural perceptions of acupuncture vary across racial and ethnic groups,” Hannah Choi, MSN, RN, a graduate research assistant at the University of Illinois Chicago, wrote in the presentation.
The aim of the study was to identify factors that may influence acupuncture expectancy for survivors of breast cancer. Expectancy was defined as the belief a treatment will be effective. The authors highlighted that this is an important driver for treatment adherence and effectiveness.
Overall, 74 women who were 18 years or older with stage 0 to III breast cancer were enrolled. This study served as the secondary analysis of baseline data from 2 acupuncture trials with a 5 and 10-week intervention.
The primary end point was acupuncture expectancy which is described as a 4-item subscale of the Attitudes and Beliefs about Complementary and Alternative Medicine Questionnaire. Social determinants of health were described as an 8-domain, 11-item questionnaire looking at social detriments of health needs like financial resources, transportation, and social connection.
Age (54 ± 10 years), race (49% Black, 45% White, and 6% Asian or Pacific Islander), education level (18% high school or below), marital status (35% married or living with a partner), and annual household income (57% less than $55,000) all played a part in the baseline demographic and clinical characteristics.
The univariate regression analysis found significant findings in financial resources (0.34; 95% CI, 0.56-0.11; P = .004), patients who were White (0.46; 95% CI, 0.01-0.92; P = .046), education of college or above (0.71; 95% CI, 0.09-1.32; P = .026), some graduate school or above (0.76; 95% CI, 0.06-1.45; P = .033), having arm pain (0.46; 95% CI, 0.003-0.91; P = .049), depression (0.30; 95% CI, –0.07 to 0.30; P = .002), stress (0.24; 95% CI, 0.01-0.47; P = .038), or social connections (0.23; 95% CI, 0.001-0.46; P = .049).
Physical function (–0.18; 95% CI, –0.41-0.05; P = .121), fatigue (–0.03; 95% CI, –0.11 to .09; P = .077), anxiety (–0.30; 95% CI, –0.28 to 0.04; P = .052), cancer stage (0.21; 95% CI, –0.02 to 0.44; P = .073), and radiation therapy (–0.48; 95% CI, –1.05 to 0.09; P = .100) were also assessed but were not found to be significant.
“Understanding these individual factors affecting acupuncture expectancy can guide integration of acupuncture into oncology care to improve quality of life for breast cancer populations,” Choi concluded.
Reference
Choi H, Doorenbos AZ, Chen Z, et al. Factors associated with acupuncture expectancy among breast cancer survivors. Presented at the 2025 Oncology Nursing Society Congress; April 9-13; Denver, CO. Poster RS69.
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.
ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC
Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
Findings from the RATIONALE-312 trial support tislelizumab plus chemotherapy as a frontline treatment option in extensive-stage small cell lung cancer.
Exploring the ESMO 2025 Presentations That May Shift GU Oncology
Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.
ROS1-Targeting Therapies Show “Suboptimal” Efficacy in ROS1-Mutated NSCLC
Although survival outcomes were numerically improved with ROS1-targeted therapies, an unmet need remains for patients with ROS1-mutated advanced NSCLC.
Awareness Fuels Progress: Upcoming Advances in Breast Cancer Treatment
Read about recent advancements in breast cancer treatment, including new therapies and survival data, showcased at the upcoming ESMO 2025 Congress.